Please login to the form below

Not currently logged in
Email:
Password:

Medius Deal Watch

This page shows the latest Medius Deal Watch news and features for those working in and with pharma, biotech and healthcare.

Latest Intelligence

  • Deal Watch October 2018

    When writing this bimonthly edition of Medius’s Deal Watch I have been struck by how often the words 'it’s unusual.' have appeared. ... Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for.

  • Deal Watch March 2017 Deal Watch March 2017

    Each month the Deal Watch team ploughs our merry way through the details of 600 plus deals to bring you the edited highlights. ... X-Chem does it again. Twice. In Japanese. X-Chem is a name that comes up with great regularity in the Deal Watch database.

  • Deal Watch February 2017 Deal Watch February 2017

    Following the enthusiastic opening to 2017, deal numbers have fallen during February as companies appear to have taken their foot off the accelerator. ... The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    On reviewing the data captured in its monthly Deal Watch reviews Medius said a significant downturn in deal activity was evident. ... This article was based on Medius' Annual Review of its Deal Watch service.

  • Deal Watch January 2017 Deal Watch January 2017

    Deal Watch January 2017. Actelion, Johnson &Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up. ... Deal Watch table spending its overseas dollars on the acquisition of Actelion for an all cash deal of $30bn (30 times price to

More from intelligence
Approximately 28 fully matching, plus 24 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics